Toll-like receptors (TLRs) activate the innate immune system in response to pathogens. Here we show that TLR9 proteolytic cleavage is a prerequisite for TLR9 signaling. Inhibition of lysosomal proteolysis rendered TLR9 inactive. The carboxy-terminal fragment of TLR9 thus generated included a portion of the TLR9 ectodomain, as well as the transmembrane and cytoplasmic domains. This cleavage fragment bound to the TLR9 ligand CpG DNA and, when expressed in Tlr9 -/-dendritic cells, restored CpG DNA-induced cytokine production. Although cathepsin L generated the requisite TLR9 cleavage products in a cell-free in vitro system, several proteases influenced TLR9 cleavage in intact cells. Lysosomal proteolysis thus contributes to innate immunity by facilitating specific cleavage of TLR9.
Toll-like receptors (TLRs) are essential sensors of microbial infection in multicellular hosts, and TLR engagement promotes the initiation of adaptive immune responses 1, 2 . The TLR family consists of 10 members in humans and 13 in mice 3, 4 . TLR1, TLR2, TLR4, TLR5 and TLR6 localize to the plasma membrane and are involved in the recognition of microbial products or lipid components [5] [6] [7] [8] [9] . TLR3, TLR7 (A002299) and TLR9 (A002301) are located in intracellular compartments and recognize pathogen-derived double-stranded RNA, single-stranded RNA and unmethylated CpG DNA, respectively [10] [11] [12] [13] [14] [15] . The intracellular localization of TLR9 is critical for the discrimination of self and non-self nucleic acids 16 . After stimulation of cells with CpG DNA, TLR9 redistributes from the endoplasmic reticulum to lysosomes, where a signaling cascade is triggered by recruitment of the MyD88 adaptor molecule 14, 17 .
The papain-like lysosomal cysteine protease family, which includes the main thiol proteases cathepsin B and cathepsin L, is important in the degradation of endocytosed and intracellular proteins 18 . At the same time, compounds that block lysosomal acidification, such as chloroquine or bafilomycin A, inhibit CpG DNA-driven signaling and responses 19 . Lysosomal proteolysis in general 20 and cathepsin K specifically 21 have also been linked to TLR9 signaling, but the molecular mechanisms underlying their involvement remain to be elucidated.
RESULTS

Cathepsin-mediated cleavage of TLR9
To investigate whether cathepsin activity is required for TLR responses, we exposed the RAW mouse macrophage cell line to pepstatin A, an inhibitor of aspartic proteases, or to z-FA-fmk, a cysteine protease inhibitor that blocks cathepsin activity; we then exposed these cells to agonists of TLR4 (lipopolysaccharide (LPS)), TLR7 (imiquimod) and TLR9 (CpG DNA). We found that z-FA-fmk considerably inhibited the production of tumor necrosis factor (TNF) by RAW macrophages stimulated with CpG DNA but did not influence TNF release after exposure to LPS or imiquimod (Fig. 1a) . Thus, lysosomal cysteine proteases inhibited by z-FA-fmk are involved in the responsiveness of TLR9 but not TLR4 or TLR7.
To establish how cathepsin activity controls TLR9 responses, we explored the fate of newly synthesized TLR9. We generated a RAW macrophage derivative that stably expressed TLR9 tagged at the carboxyl (C) terminus with Myc (TLR9-Myc) and exposed it to z-FA-fmk or DMSO. We then labeled cells for 2 h with [ 35 S]methionine and cysteine, followed by a chase for 6 h, after which we immunoprecipitated TLR9-Myc with a Myc-specific antibody. To improve electrophoretic resolution, we digested the immunoprecipitates with peptide-N-glycosidase F (Endo F), which eliminates carbohydrate heterogeneity. In the antibody to Myc (anti-Myc) immunoprecipitates of DMSO-treated cells, we detected two distinct polypeptides of 65 and 45 kilodaltons (kDa; Fig. 1b ) that were not present in the immunoprecipitates of cells labeled in the presence of z-FA-fmk (Fig. 1b) . We then denatured the initial anti-Myc immunoprecipitates and reimmunoprecipitated them with anti-Myc to retrieve TLR9-Myc. We detected the 65-kDa polypeptide in such reimmunoprecipitates from cells treated with DMSO but not those from cells exposed to z-FA-fmk (Fig. 1b) . However, we noted similar rates of TLR9 synthesis during labeling. As we were able to retrieve the 65-kDa polypeptide with the Myc-specific antibody, we concluded that it was derived from TLR9.
To explore the nature of the 65-and 45-kDa polypeptides, we treated RAW macrophages expressing TLR9-Myc with DMSO or z-FA-fmk, immunoprecipitated TLR9 with anti-Myc, resolved glycosidasedigested proteins by SDS-PAGE and visualized proteins by silver staining. We detected full-length TLR9 (about 100 kDa) in cells treated with DMSO or z-FA-fmk and detected the two polypeptides of 65 kDa and 45 kDa in cells treated with DMSO but not those treated with z-FA-fmk (Fig. 1c) . We detected interaction between the polytopic membrane protein UNC93B1 and TLR9, critical for the translocation of TLR9 to lysosomes 22, 23 , in cells treated with DMSO or z-FA-fmk ( Fig. 1c and Supplementary Fig. 1a online) . We unambiguously identified the 65-kDa and 45-kDa polypeptides as the C-terminal and amino (N)-terminal fragments of TLR9, respectively, by mass spectrometry ( Fig. 1d and Supplementary Fig. 1b) . The identification of the 45-kDa polypeptide as the N-terminal fragment of TLR9 explains why we did not retrieve it by reimmunoprecipitation with anti-Myc (Fig. 1b) . Thus, its appearance in the initial anti-Myc immunoprecipitates suggests that the N-terminal fragment interacted with full-length TLR9, with the C-terminal cleavage fragment or with both (Fig. 1b) . Fragmentation of TLR9 was readily detectable after 3 h of chase, a time frame consistent with delivery of TLR9 to lysosomes ( Supplementary Fig. 2 online) .
Identification of cleavage site(s) in the ectodomain of TLR9
To identify the likely site(s) of cleavage in TLR9, we determined the C-terminal boundary of the N-terminal segment and the N-terminal boundary of the C-terminal fragment on the basis of the unambiguous presence of peptides from these fragments as identified by mass spectrometry (Fig. 1d and Supplementary Fig. 1a ). Our analysis confined the location of possible cleavage site(s) as being a region encompassing amino acids 378-475 of TLR9 (Fig. 1d) . Because the leucine-rich repeat (LRR) regions, some of which are stabilized by disulfide bonds, form a tightly packed hydrophobic core, these regions should be less susceptible to proteolysis 24 . Secondary-structure prediction programs designated residues 441-470, which are situated between LRR14 and LRR15, as being part of a flexible loop that could render TLR9 susceptible to proteolysis (Fig. 1d) . On the basis of published TLR structures 24, 25 , we assume that the LRRs of TLRs generally take on a fairly similar fold and that LRR14 and LRR15 of TLR9 can thus be used to buttress the intervening segment of TLR9. Molecular modeling showed the presence of residues 441-470, which are contained in the putative cleavage region, in an extended loop (Fig. 1e) .
Only in the presence of z-FA-fmk did we detect an additional species of TLR9 that migrated more slowly (Figs. 1b and 2a) . Glycosidase digestion showed that this form had acquired partial resistance to Endo H (Fig. 2a) , consistent with passage through the Golgi apparatus. Because the cathepsin inhibitor z-FA-fmk was required for its visualization, this form of TLR9 is probably cleaved in lysosomes. The finding that it was normally cleaved and thus eliminated would account for the earlier failure to detect this Endo Hresistant form of TLR9 (refs. 22,23) .
Endolysosomal localization of TLR9 cleavage
To determine if the endolysosomal compartment is the location of TLR9 cleavage, we assessed the effect of z-FA-fmk on the expression, maturation and stability of wild-type TLR9 and the TLR9 chimeras TLR9-4-4 and TLR9-4-9 ( Fig. 2a) . TLR9-4-4 contains the transmembrane and cytoplasmic region of TLR4, whereas TLR9-4-9 contains only the transmembrane region of TLR4 (ref. 22) . These TLR9 chimeras fail to interact with UNC93B1 and therefore do not reach the lysosomal compartment, the presumed location of CpG DNA recognition and TLR9 signaling 22, 23 . Unlike wild-type TLR9, neither TLR9-4-4 nor TLR9-4-9 yielded the two distinct fragments (Fig. 2a) . These findings suggest that localization to the endolysosomal compartment is required for TLR9 cleavage. As TLR7 is also located in the endolysosomal compartment, we sought to determine whether TLR7, like TLR9, undergoes proteolytic processing. In the absence of the cathepsin inhibitor, in conditions in which the TLR9 cleavage products were readily detected, we retrieved only full-length TLR7 ( Supplementary Fig. 3 online) . In addition, we did not detect a mature Endo H-resistant TLR7 species in the presence of z-FA-fmk, as we did for TLR9 ( Supplementary Fig. 3 ). Next we used the vacuolar H + ATPase inhibitor bafilomycin A and the weak base chloroquine to block endosomal acidification and thus, indirectly, lysosomal protease activity 19 . Both compounds, like z-FA-fmk, blocked cleavage of TLR9 as well as CpG DNA-driven production of TNF (Fig. 2b) . In contrast, bafilomycin A and chloroquine but not z-FA-fmk suppressed imiquimod-driven production of TNF. Thus, we concluded that fragmentation of TLR9 by lysosomal proteases is inhibited by interference with lysosomal acidification; in contrast, TLR7 shows no signs of such lysosomal cleavage.
Influence of cleavage on TLR9 function
We next analyzed the interaction between CpG DNA and TLR9 in the presence and absence of z-FA-fmk (Fig. 3) . We pretreated RAW cells expressing TLR9-Myc with z-FA-fmk, followed by incubation with unlabeled CpG DNA or biotinylated CpG DNA (biotin-CpG). We recovered biotin-CpG and materials bound to it with streptavidinagarose and assessed the presence of coprecipitated TLR9-Myc by immunoblot analysis with anti-Myc. In the absence of the cathepsin inhibitor, we noted a strong interaction of the C-terminal TLR9 fragment with CpG DNA and weak but detectable binding between CpG DNA and full-length TLR9 (Fig. 3a) . As expected, given the absence of the C-terminal TLR9 cleavage fragment in lysates of cells treated with z-FA-fmk, we did not detect binding of the C-terminal TLR9 fragment to CpG DNA in z-FA-fmk-treated cells (Fig. 3a) . Notably, z-FA-fmk had no effect on the interaction between full-length TLR9 and CpG DNA, but the association between full-length TLR9 and biotin-CpG seemed to be much weaker than the interaction between CpG DNA and the C-terminal TLR9 fragment (Fig. 3a) . TLR9 molecules tagged with green fluorescent protein (GFP) showed fragmentation and binding to CpG DNA similar to that of Myc-tagged TLR9 (Fig. 3b) . A recombinantly expressed TLR9 fragment encompassing TLR9 residues 471-1032 was not cleaved further (Fig. 3c) . This recombinant C-terminal fragment, when expressed in isolation, also bound to biotin-CpG more strongly than full-length Myc-tagged TLR9 did (Fig. 4a) .
Next we sought to determine if fragmentation of TLR9 by cathepsins is critical for subsequent TLR9 signal transduction. We investigated the fragmentation of TLR9 and its interaction of CpG DNA in RAW cells stably expressing either Myc-tagged wild-type TLR9 or TLR9D441-470, a TLR9 deletion mutant lacking the proposed cleavage region (Fig. 4a,b ). TLR9D441-470 was not cleaved but was still able to bind biotin-CpG (Fig. 4a,b) . These findings suggested no gross structural alteration in the structure of the TLR9D441-470 mutant protein. To analyze the functional capacity of TLR9D441-470, we measured its ability to restore CpG DNA-induced TNF production in bone marrow-derived dendritic cells (BMDCs) from Tlr9 -/-mice. We tagged wild-type TLR9, the C-terminal cleavage fragment of TLR9 and TLR9D441-470 with GFP and expressed these by retroviral transduction in Tlr9 -/-BMDCs, then exposed these cells to CpG DNA and measured TNF production in GFP + cells by flow cytometry (Fig. 4c) .
BMDCs transduced with the TLR9D441-470 mutant produced less TNF in response to CpG DNA stimulation than did cells expressing wild-type TLR9 (Fig. 4c) . As the transmembrane segment and cytoplasmic tail of TLR9D441-470 are identical to those of full-length TLR9, and UNC93B1 bound wild-type TLR9 and TLR9D441-470 to a similar degree (data not shown), we believe that trafficking properties were unaffected by the deletion of residues 441-470.
C-terminal TLR9 fragment restores Tlr9 -/-BMDC function
We next investigated whether the C-terminal fragment, which retained a portion of the ectodomain encompassing LRR15-LRR26 and contained the full transmembrane and cytoplasmic domains, was on its own sufficient for binding to CpG DNA and initiating TLR9 signal transduction. In RAW macrophages, recombinant C-terminal TLR9 fragments tagged at the C terminus with either Myc or GFP interacted strongly with biotin-CpG, as demonstrated by the recovery of the C-terminal TLR9 fragment on streptavidin-agarose (Fig. 3b) . Neither the expression nor the molecular size of the recombinant C-terminal fragment was affected by z-FA-fmk (Fig. 3c) . Tlr9 -/-BMDCs transduced with a retrovirus encoding the recombinant GFP-tagged C-terminal fragment of TLR9 regained responsiveness to CpG DNA stimulation, as indicated by TNF production (Fig. 4c) . TNF synthesis elicited by CpG DNA stimulation of Tlr9 -/-BMDCs expressing the GFP-tagged C-terminal fragment of TLR9 was not affected by treatment with z-FA-fmk (Fig. 4d) . In contrast, TNF production facilitated by the expression of GFP-tagged wild-type TLR9 in Tlr9 -/-BMDCs was inhibited by z-FA-fmk (Fig. 4d) . The greater sensitivity of BMDCs to cytotoxic effects of z-FA-fmk did not allow us to use the inhibitor concentrations readily tolerated by RAW cells and their derivatives to achieve full inhibition of TNF production. Nevertheless, we conclude that the C-terminal TLR9 fragment on its own is sufficient to bind CpG DNA and initiate signaling.
Multistep TLR9 cleavage
If indeed residues 441-470 are correctly modeled as a flexible loop (Fig. 1e) , then any of a number of proteases could presumably cleave it, as has been noted for other proteins activated by proteolysis, such as flu hemagglutinin, cholera toxin and various proenzymes, including lysosomal hydrolases. Similarly, although the involvement of lysosomal proteolysis in major histocompatibility class II-restricted antigen presentation is immediately evident from the inhibitory effects of a broad protease blockade, with very few exceptions, it has been difficult to link any particular protease to the processing of a specific antigen 26, 27 . For the same reasons, it may be difficult to determine which members of the cathepsin family of lysosomal proteases cleave TLR9. After genetic ablation or pharmacological inhibition of a single cathepsin, any of several cysteine proteases could 'pick up the slack' , thereby explaining the greater inhibitory potency of the broadly specific inhibitors over more narrowly targeted compounds 28, 29 . Also, mice lacking multiple cathepsins have more severely deleterious phenotypes than those of mice lacking a single cathepsin 30 . Nonetheless, we examined the TLR responsiveness of BMDCs from mice lacking individual cathepsins. Cathepsin L-deficient BMDCs and, to a lesser extent, cathepsin S-deficient BMDCs produced less TNF in response to CpG DNA (Fig. 5a) . We noted normal TNF production in response to CpG DNA by BMDCs from cathepsin K-deficient mice, which seemed at variance with a published report 21 in which cathepsin K-deficient BMDCs failed to respond to CpG DNA stimulation, as assessed by their lower production of interleukin 12.
We next examined the effects of a series of selective cathepsin inhibitors on the pattern of TLR9 cleavage in and TNF production by RAW cells. We found that z-FA-fmk, but not any of the more narrowly specific cathepsin inhibitors, completely suppressed formation of the 65-kDa C-terminal TLR9 fragment itself (Fig. 5b) . Cleavage in the presence of the cathepsin K inhibitor was indistinguishable from cleavage in the presence of DMSO (Fig. 5b) . Selective inhibition of cathepsin L or cathepsin S resulted in the appearance of a doublet composed of a slightly larger band in addition to the 65-kDa band (Fig. 5b) . We called the upper band the 'pre-C-terminal fragment' . The cathepsin K inhibitor, when combined with other inhibitors, failed to produce an additive effect (Fig. 5b) . However, combining the cathepsin S-and cathepsin L-selective inhibitors resulted in enrichment of the pre-C-terminal fragment relative to the C-terminal fragment (Fig. 5b) . The pre-C-terminal fragment seemed to be inactive, as we noted a strict inverse correlation between its presence and TNF production (Fig. 5b) . Partial conversion of full-length TLR9 to the pre-C-terminal and C-terminal fragments yielded intermediate amounts of TNF. The slight difference in apparent molecular weight suggested that at most a few dozen residues distinguished the active C-terminal fragment from the inactive TLR9 pre-C-terminal fragment (Fig. 5b) . These data suggest that at least two cleavage events occur to convert full-length TLR9 into its active form ( Supplementary Fig. 4 online). In addition, introduction of the C-terminal TLR9 fragment into cathepsin L-deficient BMDCs restored CpG DNA-driven production of TNF (Fig. 5c) . Wild-type TLR9 restored TNF production to a limited extent, consistent with the limited inhibition of TNF production of untransduced cathepsin L-deficient BMDCs (Fig. 5a,c) .
We conclude that more than a single lysosomal protease is involved in cleavage of TLR9, with an important function for cathepsin L.
To further support the idea that cathepsin L can cleave TLR9 at the proposed cleavage site, we incubated radiochemically pure TLR9, produced by in vitro translation in the presence of properly redoxbuffered microsomes 31 , with purified cathepsin L (Fig. 6a) . Cathepsin L produced the C-terminal fragment of TLR9 in vitro (Fig. 6a) , and this C-terminal fragment bound to biotin-CpG (Fig. 6b) . However, the TLR9 deletion mutant TLR9D441-470 was not cleaved by cathepsin L in vitro (Fig. 6a) . Our results collectively establish that TLR9 undergoes cleavage in an endolysosomal compartment, a step that is important for TLR9 to execute its proper function.
DISCUSSION
The involvement of the endolysosomal compartment in proper functioning of the nucleic acid-sensing TLRs (TLR3, TLR7 and TLR9) is well documented [11] [12] [13] [14] [15] [16] , but exactly how this environment contributes to the receipt and transmission of signals through these TLRs has not been established. We have now demonstrated that TLR9 underwent proteolytic cleavage, executed by cysteine proteases, in the endolysosomal compartment. On a molar basis, the C-terminal cleavage fragment of TLR9 bound CpG DNA more strongly than did full-length TLR9, although full-length TLR9 did bind CpG DNA.
The broadly specific inhibitor z-FA-fmk was most effective at blocking this cleavage and, accordingly, abrogated TNF production in cells exposed to the TLR9 agonist CpG DNA. Our data are consistent with the involvement of more than one protease in this cleavage reaction, because we noted a blunted rather than a completely blocked TNF response to CpG DNA in BMDCs deficient in cathepsin L or cathepsin S. Furthermore, a combination of inhibitors selective for cathepsin L and cathepsin S not only blocked TNF production in response to CpG DNA but also yielded a cleavage intermediate, the pre-C-terminal fragment, whose abundance was inversely correlated with TNF production. The expression of only the C-terminal fragment in Tlr9 -/-BMDCs restored their ability to produce TNF, as also noted for cathepsin L-deficient BMDCs. We hypothesize that the absence of cleavage in the presence of chloroquine and bafilomycin A is best explained by higher pH or less proteolytic activity.
The delivery of TLR9 to endolysosomal compartments requires its interaction with UNC93B1, mediated through the transmembrane segment of TLR9 (ref. 22) . Eliminating this interaction by substituting the transmembrane segment of TLR9 causes TLR9 to traffic incorrectly to the surface 16 , and mutating the gene encoding UNC93B1 abolishes trafficking of TLR9 to the endolysosomal compartment 23 . The ability of a chimera consisting of the extracellular domain of TLR9 and the transmembrane and cytoplasmic domains of TLR4, which localizes to the cell surface, to induce signal transduction after CpG DNA binding might be attributed to the recruitment of adaptors other than MyD88 to the TLR4 cytoplasmic tail 16, 32 .
We did not find any inhibition of TNF production in cathepsin K-deficient BMDCs or by imposition of a cathepsin K blockade, in contrast to an earlier study that showed less production of interleukin 12 by cathepsin K-deficient BMDCs in response to CpG DNA 21 . We further determined that responses requiring the engagement of TLR7 were not affected by z-FA-fmk, unlike the blockade in upregulation of CD86 and B cell proliferation reported earlier 20 . The production of interleukin 12 may require the involvement of cathepsin K at steps 'downstream' of TLR9 engagement, which could explain the observed discrepancy. Likewise, the surface expression of CD86 and steps that control B cell proliferation may require lysosomal protease involvement for reasons other than cleavage of the TLRs involved.
We obtained no evidence that TLR7 is cleaved in a z-FA-fmksensitive way, and we have been unable to detect cleavage fragments of TLR7. This raises the issue of why signaling through TLR7, or through TLR3, for that matter, is nonetheless sensitive to the inclusion of lysosomotropic agents. Several of the TLRs are known to act together with partner proteins, such as CD14 and MD2 for TLR4 (refs. 33,34), CD36 for TLR1, TLR2 and TLR6 (ref. 35 ), or dectin-1 for TLR2 (ref. 36) . We hypothesize that the activity of TLR3 and TLR7 may require cofactors whose involvement necessitates a proteolytic cleavage, or at least includes a pH-sensitive step, that is affected by the inclusion of lysosomotropic agents. The evolutionary importance of TLR9 cleavage is as yet unclear. Why should TLR9 be unique among lysosomal TLRs in requiring this mode of activation? The C-terminal cleavage fragment of TLR9 was able to bind CpG DNA and accomplish signal transduction even when synthesized in the absence of the N-terminal portion of TLR9. A search for interaction partners of the N-terminal cleavage fragment might elucidate yet other aspects of TLR9 biology. Regardless of the identity of the TLR9 convertase(s) and the exact function of the cleavage products generated, full innate immunity requires lysosomal proteolysis no less than adaptive immunity does.
METHODS
Reagents. Imiquimod (R837) and polyinosinic-polycytidylic acid were from Invivogen; 1826 CpG DNA and 1826 biotinylated CpG DNA (5¢-BioTsCsCsAsTsgsAsCsgsTsTsCsCsTsgsAsCsgsTsT) were from TIB Molbiol; and LPS (Escherichia coli serotype 026:B6) and brefeldin A were from Sigma. Endo H and Endo F were from New England Biolabs. Monoclonal anti-Myc (9B11), rabbit polyclonal anti-rabbit GFP (ab290) and rabbit polyclonal anti-TLR7 (IMG-5632) were from Cell Signaling, Abcam and Imgenex, respectively. Streptavidin-agarose beads were from Pierce. Bafilomycin, chloroquine, z-FAfmk (benzyloxycarbonyl-phenylalanine-alanine-fluoromethylketone) and glutathione disulfide were from Sigma, and the cathepsin B inhibitor CA-074Me ((L-3-trans-(propylcarbamoyl)oxirane-2-carbonyl)-L-isoleucyl-L-proline methyl ester) was from Calbiochem. The selective cathepsin inhibitors Clik195 and Clik148 (cathepsin L), LHVS (cathepsin S) and cathepsin K inhibitor II (cathepsin K; Calbiochem) were provided by G.-P. Shi 37 .
Mice and cell lines. C57BL/6 mice were from Charles River Laboratories; Tlr9 -/-mice were from A. Marshak-Rothstein. All animals were maintained in specific pathogen-free conditions according to guidelines of the committee for animal care at the Whitehead Institute. Mouse RAW 264.7 macrophages (TIB-71; American Type Culture Collection) and human embryonic kidney cells (HEK293T; CRL-11268; American Type Culture Collection) were cultured in DMEM supplemented with 10% (vol/vol) heat-inactivated FCS and penicillin-streptomycin. Cells were grown at 37 1C in humidified air with 5% CO 2 . Mice deficient in cathepsin L, cathepsin S and cathepsin K were provided by G.-P. Shi. DNA cloning. All mouse TLR9 constructs were fused at the C terminus to Myc or GFP. Wild-type TLR9 and TLR9 chimeras have been described 22 . The TLR9 deletion mutant lacking residues 441-470 was generated by sequential PCR with the primers 5¢-CTGTCAGAAGCCACCCCTGAAGAGTGTAAGAACTT CAAGTTCACCATGGACCTG-3¢ (forward) and 5¢-CAGGTCCATGGTGAAC TTGAAGTTCTTACACTCTTCAGGGGTGGCTTCTGAGAC-3¢ (reverse). The recombinant C-terminal TLR9 fragment encompassing residues 471-1032 was generated by PCR with the primers 5¢-GGGGTACCTGTAAGAACTTC AAGTTCACCATGGACCTG-3¢ (forward) and 5¢-AGCTTTGTTTAAACTTTA CAAGTCCTCTTCAGAAATGAGCTTTTGCTCTTCTGCTGTAGGTCCCCGG CAGA-3¢ (reverse). The C-terminal TLR9 fragment encompassing residues 471-1032 was fused at the N terminus with the H-2K b signal sequence (MVPCTLLLLLAAALAPTQTRA). All constructs were cloned into pcDNA3.1(+) (Invitrogen) or the retroviral pMSCV vector (Clontech) and were verified by sequencing.
Preparation of BMDCs. BMDCs were prepared as described 38 .
Pulse-chase analysis, immunoprecipitation and Endo H-Endo F assay. RAW macrophages (1 Â 10 7 ) were 'starved' for 50 min in medium lacking methionine and cysteine (starvation medium), then were labeled with a mixture of [ 35 S]methionine and [ 35 S]cysteine (0.1 mCi/nl; Perkin Elmer) in starvation medium supplemented with dialyzed heat-inactivated FCS, followed by a chase in complete medium with or without 10 mM inhibitor. Cells were lysed for 1 h at 4 1C with 1% (vol/vol) Nonidet-P40 in PBS supplemented with protease inhibitors (Roche). After lysates were precleared with protein GSepharose (Sigma-Aldrich), primary antibodies and protein G-Sepharose were added to supernatants, followed by incubation at 4 1C. The protein G-Sepharose beads were washed five times with 0.1% (vol/vol) Nonidet-P40 in PBS. Proteins were eluted from the beads by boiling in SDS sample buffer and were separated by SDS-PAGE, and polypeptides were visualized by fluorography. Where indicated, samples were digested for 3 h at 37 1C with Endo H and Endo F.
Coimmunoprecipitation and immunoblot analysis. Cells were lysed in 1% (vol/vol) digitonin (Calbiochem) in buffer containing 25 mM HEPES, 100 mM NaCl, 10 mM CaCl 2 and 5 mM MgCl 2 , pH 7.6, supplemented with 0.5 mM phenylmethylsulfonylfluoride and leupeptin. Lysates were precleared for 1 h at 4 1C with protein G-Sepharose (Sigma-Aldrich). For immunoprecipitation, samples were incubated for 12 h at 4 1C with the appropriate antibodies before protein G beads were added for 3 h. Beads were washed four times with 0.1% (vol/vol) digitonin, and bound proteins were eluted by boiling in SDS sample buffer or 1% (vol/vol) SDS. Proteins were separated by 10% SDS-PAGE, were transferred to nitrocellulose membranes, were blocked for 2 h with 5% (wt/vol) skim milk in PBS with 0.1% (vol/vol) Tween-20 and were probed for 4 h with the appropriate antibodies. Membranes were washed three times with PBS with 0.1% (vol/vol) Tween-20 and were incubated for 1 h with horseradish peroxidase-conjugated streptavidin. Proteins were visualized with an enhanced chemiluminescence detection reagent.
Large-scale affinity purification and mass spectrometry. After coimmunoprecipitation, eluted samples were separated by SDS-PAGE and polypeptides were visualized by silver staining. Bands of interest were excised, were lysed with trypsin and were analyzed by tandem mass spectrometry.
Retroviral transduction. HEK293T cells were transfected with plasmids encoding VSV-G and Gag-Pol, as well as pMSCV-TLR9-Myc, pMSCV-TLR9-4-4-Myc, pMSCV-TLR9-4-9-Myc, pMSCV-TLR9D441-470 or pMSCV-TLR9 471-1032. At 24 h and 48 h after transfection, medium containing viral particles was collected, was filtered through a 0.45-mm membrane and was added to RAW macrophages or BMDCs at day 1 of BMDC culture. The next day, cells were given fresh media.
In vitro transcription and translation. Myc-tagged wild-type TLR9, TLR9D441-470 or the C-terminal TLR9 fragment of residues 471-1032 cloned into the pcDNA3.1(+) vector (1 mg) was transcribed and translated for 1 h at 30 1C in vitro with the TNT T7 Quick Coupled Transcription/Translation system (Promega) in the presence of microsomes and 10 mCi [ 35 S]methionine (Perkin Elmer) in a total volume of 50 ml. Microsomes were pelleted by centrifugation for 4 min at 17,000g and were lysed in 20 ml cathepsin activation buffer (1% (vol/vol) Nonidet-P40, 50 mM sodium actetate, pH 5.5, 3 mM cysteine and 1 mM EDTA). Recombinant cathepsin L (Sigma) was immediately added to the microsomes at a concentration of 0.1-0.2 mM and incubated for 2 h at 37 1C, followed by incubation for 2 h at 37 1C with biotinylated CpG DNA (5 mM). Reactions were diluted to a final volume of 1 ml with 1% (vol/vol) Nonidet-P40 lysis buffer with protease inhibitors, and TLR9 proteins were immunoprecipitated with anti-Myc or were incubated with streptavidin agarose and separated by SDS-PAGE.
Intracellular TNF assay. Tlr9 -/-BMDCs expressing either wild-type or mutant TLR9 were cultured for 5 d and were stimulated for 4 h with CpG DNA (1 mM) in the presence of brefeldin A (10 mg/ml). Cells were fixed for 10 min at 20 1C with 4% (vol/vol) formaldehyde and were made permeable by incubation for 10 min with 0.5% (wt/vol) saponin in flow cytometry buffer (PBS with 2% (wt/vol) BSA and 0.05% (wt/vol) sodium azide). Cells were stained for 30 min with Alexa Fluor 647-conjugated anti-TNF (MP6-XT22; 557730; BD Biosciences). Fluorescence intensity was measured with LSR I flow cytometer (BD Biosciences). Data were collected with CellQuest software (BD Biosciences) and were analyzed with FlowJo software (TreeStar).
TNF enzyme-linked immunosorbent assay. RAW macrophages were stimulated for 2 h with increasing concentrations of the TLR agonists LPS (TLR4), imiquimod (TLR7) or CpG DNA (TLR9). Conditioned medium was collected and was analyzed by enzyme-linked immunosorbent assay with hamster antibody to mouse or rat TNF (557516; BD Biosciences) as a capture antibody and biotin-labeled rabbit anti-mouse as a secondary antibody (557432; BD Biosciences).
Homology modeling. A multiple sequence alignment containing the target sequence (Mus musculus TLR9; National Center for Biotechnology Information accession number NP_112455) and the template sequence (Mus musculus TLR3; National Center for Biotechnology Information accession number NP_569054) was generated by the ClustalW program. The resulting alignment and the structure of the Mus musculus TLR3 ectodomain (Protein Data Base accession code 3ciy, chain A) were used to generate a structural model of the Mus musculus TLR9 ectodomain with the Swiss-Model automated comparative protein modeling server 39 .
Accession codes. UCSD-Nature Signaling Gateway (http://www.signaling-gate way.org): A002299 and A002301.
Note: Supplementary information is available on the Nature Immunology website.
